{
    "Trade/Device Name(s)": [
        "AESKULISA \u03b22-Glyco-A Protocol 30-30-30",
        "AESKULISA \u03b22-Glyco-A Protocol 30-15-15",
        "AESKULISA \u03b22-Glyco-GM Protocol 30-30-30",
        "AESKULISA \u03b22-Glyco-GM Protocol 30-15-15",
        "AESKULISA \u03b22-Glyco-Check Protocol 30-30-30",
        "AESKULISA \u03b22-Glyco-Check Protocol 30-15-15"
    ],
    "Submitter Information": "AESKU, Inc.",
    "510(k) Number": "K062217",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MSV"
    ],
    "Summary Letter Date": "December 13, 2006",
    "Summary Letter Received Date": "August 3, 2006",
    "Submission Date": "July 31, 2006",
    "Regulation Number(s)": [
        "21 CFR 866.5660"
    ],
    "Regulation Name(s)": [
        "Multiple Autoantibodies Immunological Test System"
    ],
    "Analyte Class(es)": [
        "autoimmune",
        "immunology"
    ],
    "Analyte(s)": [
        "IgA antibodies against \u03b22 glycoprotein I",
        "IgG antibodies against \u03b22 glycoprotein I",
        "IgM antibodies against \u03b22 glycoprotein I"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay (EIA)"
    ],
    "Methodologies": [
        "Solid phase enzyme immunoassay"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for AESKULISA \u03b22-Glyco enzyme immunoassays for detection of anti-\u03b22 glycoprotein I antibodies in human serum",
    "Indications for Use Summary": "Semiquantitative and qualitative detection of IgA, IgG, and/or IgM antibodies against \u03b22 glycoprotein I in human serum to aid in the diagnosis of thrombotic disorders related to primary and secondary antiphospholipid syndrome",
    "fda_folder": "Immunology"
}